(Q83292338)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

title

Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

phase II clinical trial

1 reference

1 reference

hepatocellular carcinoma

1 reference

1 reference

Weijing Sun

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Davendra Sohal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Daniel G Haller

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kristine Mykulowycz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Mark Rosen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Michael C Soulen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Millie Caparro

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Ursina R Teitelbaum

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Bruce Giantonio

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Peter J O'Dwyer

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Abraham Shaked

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Rajender Reddy

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Kim Olthoff

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

publication date

24 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

117

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

3187-3192

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

Global cancer statistics, 2002

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Rising incidence of hepatocellular carcinoma in the United States

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Sorafenib in advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Effect of the etiology of viral cirrhosis on the survival of patients with hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Clinical characteristics of NonBNonC- HCC: Comparison with HBV and HCV related HCC.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

The biology of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Bevacizumab: current indications and future development for management of solid tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25889

7 January 2021

Identifiers

DOI

10.1002/CNCR.25889

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21264839%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

1 reference